AstraZeneca Launches Ultomiris in China for gMG and NMOSD Treatments
UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has announced the launch of Ultomiris (ravulizumab), a...
Company
AstraZeneca Pauses GBP 200m Cambridge R&D Investment Amid UK Funding Cuts
On September 12, 2025, AstraZeneca (AZ; NASDAQ: AZN) confirmed it has paused its GBP 200m...
Novo Nordisk Rybelsus Gains Cardio Benefit from SOUL Trial
Novo Nordisk A/S (NYSE: NVO) announced that the European Medicines Agency (EMA)’s Committee for Medicinal Products...
Sino Biopharmaceutical Secures NMPA Approval for Degarelix Generic in China
Sino Biopharmaceutical Limited (HKG: 1177) announced that its subsidiary Jiangsu Chia Tai Tianqing Pharmaceutical Co.,...
Haisco Pharma Secures NMPA Approval for Anrikefon in Hemodialysis‑Related Pruritus
Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that the China National Medical Products Administration...
Monte Rosa Therapeutics and Novartis Partner on Degrader Development
Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) announced today a new collaboration with Novartis (NYSE: NVS)...
Shenzhen Kangtai Receives NMPA Approval for Sabin‑Strain Inactivated Polio Vaccine
Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) announced today that the China National Medical...
Biocytogen Licenses RenMice Antibody to Tubulis, Boosting ADC Development
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced today that it has entered into a...
Bio-Thera Partners with Jamjoom Pharma to Launch BAT2306 Biosimilar in MENA
Guangzhou-based Bio-Thera Solutions Ltd. (SHA: 688177) announced on September 15, 2025, that it has entered...
ZSCO Invests 790 m RMB in Guobang Pharma, Launches Strategic Partnership
Zhejiang State‑owned Capital Operation Co., Ltd. (ZSCO) and Guobang Pharmaceutical (SHA: 605507) announced a strategic...
CSPC Pharmaceutical Group Secures NMPA Approval for SYH2066 in RSV Trials
CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its novel oral small‑molecule, SYH2066, has been...
Genrix Succeeds with Telikibart Phase 3, Targets Atopic Dermatitis
China‑based Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA: 688443) announced today that its telikibart (GR1802) injection...
HitGen and BioAge Launch Phase I Study of BGE‑102, a Novel NLRP3 Inhibitor
China‑based HitGen Inc. (SHA: 688222) announced that its partner, BioAge Labs, Inc. (NASDAQ: BIOA), has...
Biokin Pharma Secures Breakthrough Therapy Designation for izalontamab with BMS
China‑based Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced today that its bispecific antibody‑drug conjugate...
Siemens Healthineers Diagnostics Sale: Blackstone, CVC, KKR Explore €6 B Deal
Siemens Healthineers AG (ETR: SHL), a Germany-based medical device giant is reportedly in exploratory talks...
Baheal’s 24% Take‑over of Tianjin Jikun Secures Rights to Pulmonary Fibrosis Drug JK1033
China‑based Baheal Pharmaceutical Group (SHE: 301015) announced a strategic cooperation agreement with Tianjin Jikun Pharmaceutical...
BMS Sells 60% Shanghai Stake to Hillhouse Capital, Shifting Focus to Growth
A leaked internal email from US major Bristol-Myers Squibb (BMS; NYSE: BMY) has recently surfaced...
CSPC Pharmaceutical Group Submits Anbenitamab for NMPA Approval in HER2‑Positive Gastric Cancer
CSPC Pharmaceutical Group (HKG: 1093) announced today that Anbenitamab Antibody Injection (KN026), co‑developed with Alphamab...
BioNTech and BMS Reveal Promising Interim Results for Pumitamig in ES‑SCLC
BioNTech SE (NASDAQ: BNTX) and Bristol-Myers Squibb (BMS, NYSE: BMY) disclosed interim data from a...
Summit Therapeutics Presents 2025 HARMONi Study Results at World Lung Cancer Conference
Summit Therapeutics (NASDAQ: SMMT) disclosed longer‑term progression‑free survival (PFS) data from its HARMONi trial of...